- For people with severe aortic stenosis without symptoms, surgery is not always recommended if their quality of life is not affected and their risk for further complications is low.
- A new study determined that even when patients have asymptomatic severe aortic stenosis and did not need symptom relief, early surgery was still beneficial because it decreased their risk of death and of cardiovascular events such as heart attack, stroke or heart failure.
Embargoed until 8:30 a.m. CT/9:30 a.m. ET Saturday, Nov. 13, 2021
(NewMediaWire) – November 13, 2021 – DALLAS – For people experiencing severe aortic stenosis who do not have symptoms or need symptom relief, early aortic valve replacement surgery may be beneficial because it reduces the risk of death, heart attack, stroke and heart failure, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2021. The meeting is fully virtual, Saturday, November 13-Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide.
The heart pumps blood to the rest of the body through the aortic valve. Aortic stenosis occurs if the opening of the valve narrows and restricts blood flow, which may be due to a congenital condition or calcium buildup. Aortic stenosis is one of the most serious and common valve diseases, with 20% of older Americans in the U.S. diagnosed with the condition. Treatment for aortic stenosis can depend on the severity and symptoms. For mild or moderate cases, health professionals may opt for watchful waiting, which is regular monitoring and management to determine if symptoms develop.
For people with severe aortic stenosis who experience symptoms, which may include chest pain or tightness, fatigue, shortness of breath or swelling in the feet and ankles, surgery to replace the aortic valve is the best option to improve symptoms, survival and quality of life. Determining if surgery is the best option isn’t as clear when a patient has severe aortic stenosis yet does not experience symptoms and cardiac function is still adequate.
“Managing an asymptomatic patient with severe aortic stenosis can make for a much more difficult decision since valve replacement is not needed to improve the person’s quality of life, and the risk of sudden cardiac death is perceived to be low — around 1% per year, though still higher than in the general population,” said Marko Banovic, M.D., Ph.D., lead investigator of the trial and an associate professor of cardiology at University Clinical Center of Serbia and the University of Belgrade Medical School in Serbia. “Another factor to consider, though, is that sustained pressure overload of the left heart chamber in severe aortic stenosis during a watchful waiting period is associated with structural and functional cardiac impairment. Without treatment, these impairments may progress and become irreversible by the time valve replacement surgery is done, and there may be potentially more serious complications including heart attack, stroke and death.”
The study, the Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis (AVATAR) trial, was designed to evaluate the safety and effectiveness of performing aortic valve replacement surgery earlier for adults who are asymptomatic and have normal left ventricle function. The study was conducted at nine centers across seven European countries and included a total of 157 adults, 57% men, with an average age of 67 years.
All study participants were confirmed to have no symptoms associated with severe aortic stenosis via standardized exercise testing, and they did not have any significant health conditions such as severe lung disease, chronic kidney disease or an overall high surgical risk. The patients were randomly assigned to have early surgery (78 patients) or to receive conservative, non-surgical treatment of watchful waiting (79 patients), in accordance with current treatment guidelines.
Analysis of both study groups found:
- 72 participants in the early surgery group received an aortic valve replacement. After an average follow-up of 32 months, they had lower rates of combined death, heart attack, stroke or unplanned hospitalization for heart failure compared to the watchful waiting group.
- Only 13 patients in the early surgery group experienced one or more of cardiac issues (death, heart attack, stroke or unplanned hospitalization for heart failure), compared to 26 people in the non-surgical treatment group.
- One person in the early surgery group died within 30-days after the operation. Banovic noted the 1.4% intra-operative mortality rate in this group aligned with the anticipated mortality for elective isolated surgical aortic valve replacement.
“We believe our results provide new evidence to aid clinicians when they are considering treatment options for those patients who have undergone systematic exercise testing to assess truly asymptomatic aortic stenosis with mainly progressive disease and normal left ventricular function,” Banovic said. “Our data deliver the additional degree of evidence needed to support the decision for early surgery and reassure a clinician when caring for a patient with severe asymptomatic aortic stenosis and normal left ventricular function. In such cases of low surgical risk and absence of other major health conditions, one may advocate for an early surgery for select patients.”
Co-authors are Martin Penicka, M.D., Ph.D.; Gheorghe Doros, Ph.D.; Marek Deja, M.D., Ph.D.; Radka Kockova, M.D.; Martin Kotrc, M.U.Dr.; Sigita Glaveckaite, M.D., Ph.D.; Hrvoje Gasparovic, M.D., Ph.D.; Nikola Pavlovic, M.D., Ph.D.; Lazar Velicki, M.D.; Stefano Salizzoni, M.D., Ph.D.; Wojciech Wojakowski, M.D.; Guy Van Camp, M.D., Ph.D.; Serge Nikolic, M.D.; Bernard Iung, M.D., M.S.; and Jozef Bartunek, M.D., Ph.D. Authors’ disclosures are listed in the abstract.
The authors did not report any funding for the study.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, November 13 through Monday, November 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective: